Unlocking the power of cannabioids for treatment of serious neurological and inflammatory conditions

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Vitality is developing proprietary cannabinoid pharmaceuticals that are compliant with FDA and DEA regulations. Oral cannabinoid pharmaceuticals are a convenient and desirable option for patients and physicians, and they could help realize the full therapeutic potential of cannabinoid medicines.

Oral prodrugs enable a regulatory strategy with lower risk that is akin to specialty pharmaceutical development. The company benefits from existing clinical studies of cannabinoids demonstrating their effectiveness in treating in IBD, NBS, MS, neuropathic pain, and additional disease indications.

Beyond drug development, Vitality is launching a network of treatment centers across the U.S. focused on use of treatment of chronic pain and reduction of opiate dependence. The Company is developing proprietary therapies and treatment regimens including ones that use cannabinoids as an alternative to opiate painkillers.